OR WAIT null SECS
October 12, 2021
Our latest numbers crunch on biopharma financial performance—this one assessing growth and value-generation during the heart of COVID-19—reveals a mix of the familiar and new entrants into the top spots in seven business-critical metrics.
While Q3 numbers look bleak, is improvement on the horizon?
September 14, 2021
Though M&A activity and equity market outputs have been mixed, and pandemic challenges linger on, the outlooks for pharma and biotech remain stable—driven by R&D gains, record IPO levels.
When was the last time a big pharma’s shares massively outperformed a biotech index YTD? Hint: You likely weren’t around.
August 27, 2021
With large M&A deals comes a complex Market Authorization Transfer (MAT) process, during which regulatory teams must weigh several operational aspects while creating a roadmap that takes them into account. Cecile Riboud outlines some key questions that are necessary for planning and executing a successful MAT process.
August 10, 2021
But could there be a shift in momentum?
July 26, 2021
Biopharma deal-making is on the rise again and now is the time for biopharma companies to embrace M&As to prepare for future growth.
July 08, 2021
A remarkable run indeed, but cost questions can’t be ignored.
June 09, 2021
What are the reasons behind the slump and what does the future hold?
May 21, 2021
The recent flurry of Q1 earnings reports offer a unique opportunity to assess the real-time impacts of COVID-19 on the sector.
